By Ben James ( February 21, 2008, 12:00 AM EST) -- Amgen Inc. reiterated its desire for a permanent injunction barring F. Hoffman-La Roche Ltd.'s anemia treatment Mircera from the U.S. market, in response to the Swiss company's proposal to make the peg-EPO product available to patients in America and pay Amgen a 20% royalty on Mircera's U.S. sales....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.